Incyte Corporation (BIT:1INCY)
55.20
0.00 (0.00%)
Last updated: May 7, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
JAKAFI | 2.93B |
Log In |
Log In |
Log In |
Log In |
JAKAFI Growth | 13.31% |
Log In |
Log In |
Log In |
Log In |
Total Product | 3.81B |
Log In |
Log In |
Log In |
Log In |
Total Product Growth | 19.03% |
Log In |
Log In |
Log In |
Log In |
JAKAVI Product Royalty | 421.39M |
Log In |
Log In |
Log In |
Log In |
JAKAVI Product Royalty Growth | 10.75% |
Log In |
Log In |
Log In |
Log In |
Total Product Royalty | 583.99M |
Log In |
Log In |
Log In |
Log In |
Total Product Royalty Growth | 9.36% |
Log In |
Log In |
Log In |
Log In |
Milestone and Contract | - |
Log In |
Log In |
Log In |
Log In |
Milestone and Contract Growth | - |
Log In |
Log In |
Log In |
Log In |
ICLUSIG | 113.52M |
Log In |
Log In |
Log In |
Log In |
ICLUSIG Growth | -0.67% |
Log In |
Log In |
Log In |
Log In |
OLUMIANT Product Royalty | 135.78M |
Log In |
Log In |
Log In |
Log In |
OLUMIANT Product Royalty Growth | 2.42% |
Log In |
Log In |
Log In |
Log In |
PEMAZYRE | 82.51M |
Log In |
Log In |
Log In |
Log In |
PEMAZYRE Growth | 4.65% |
Log In |
Log In |
Log In |
Log In |
TABRECTA Product Royalty | 23.93M |
Log In |
Log In |
Log In |
Log In |
TABRECTA Product Royalty Growth | 26.92% |
Log In |
Log In |
Log In |
Log In |
OPZELURA | 541.27M |
Log In |
Log In |
Log In |
Log In |
OPZELURA Growth | 47.47% |
Log In |
Log In |
Log In |
Log In |
MINJUVI | 124.91M |
Log In |
Log In |
Log In |
Log In |
MINJUVI Growth | 129.73% |
Log In |
Log In |
Log In |
Log In |
Other Product Royalty | 2.89M |
Log In |
Log In |
Log In |
Log In |
Other Product Royalty Growth | 37.38% |
Log In |
Log In |
Log In |
Log In |
ZYNYZ | 5.73M |
Log In |
Log In |
Log In |
Log In |
ZYNYZ Growth | 233.55% |
Log In |
Log In |
Log In |
Log In |